Churg-Strauss syndrome: Difference between revisions

Line 6: Line 6:


==Clinical Features==
==Clinical Features==
*Classically develops in three sequential phases:
Classically develops in three sequential phases:
*#Prodrome
#Prodrome
*#*Atopic diseases, allergic rhinitis, and asthma
#*Atopic diseases, allergic rhinitis, and asthma
*#Eosinophilic phase
#Eosinophilic phase
*#*Multiorgan involvement, particularly lung and GI tract
#*Multiorgan involvement, particularly lung and GI tract
*#*Caused by eosinophilic infiltration into these organs
#*Caused by eosinophilic infiltration into these organs
*#Vasculitic phase  
#Vasculitic phase  
*#*Life threatening vasculitis associated with vascular and extravascular granulomatosis
#*Life threatening vasculitis associated with vascular and extravascular granulomatosis
*#*May present with nonspecific signs such as fever, weight loss, malaise
#*May present with nonspecific signs such as fever, weight loss, malaise


==Differential Diagnosis==
==Differential Diagnosis==

Revision as of 11:18, 7 February 2016

Background

  • Eosinophilic granulomatosis with polyangiitis (EGPA)
  • Chronic sinusitis, asthma, and peripheral eosinophilia
  • Vasculitis of small and medium sized vessels
  • Lung and skin are most commonly involved

Clinical Features

Classically develops in three sequential phases:

  1. Prodrome
    • Atopic diseases, allergic rhinitis, and asthma
  2. Eosinophilic phase
    • Multiorgan involvement, particularly lung and GI tract
    • Caused by eosinophilic infiltration into these organs
  3. Vasculitic phase
    • Life threatening vasculitis associated with vascular and extravascular granulomatosis
    • May present with nonspecific signs such as fever, weight loss, malaise

Differential Diagnosis

  • Aspirin-exacerbated respiratory disease
  • Chronic eosinophilic pneumonia
  • Allergic bronchopulmonary aspergillosis
  • Hypereosinophilic syndrome
  • Other vasculitides

Diagnosis

  • Typically a clinical diagnosis
  • Labs with elevated eosinophils, ESR, CRP, ANCA
  • CXR with transient, patchy opacities

Management

  • Initiation Therapy
    • Prednisone 0.5-1.5 mg/kg/day
    • Cyclophosphamide
  • Maintenance Therapy
    • Azathioprine
    • Methotrexate
    • Leflunomide
    • Inhaled glucocorticoids

Disposition

  • Refer to rheumatology

See Also

External Links

References

<UpToDate>